Cargando…
Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224379/ https://www.ncbi.nlm.nih.gov/pubmed/34064300 http://dx.doi.org/10.3390/pathogens10060636 |
_version_ | 1783711877452267520 |
---|---|
author | Hudakova, Nikola Hricikova, Simona Kulkarni, Amod Bhide, Mangesh Kontsekova, Eva Cizkova, Dasa |
author_facet | Hudakova, Nikola Hricikova, Simona Kulkarni, Amod Bhide, Mangesh Kontsekova, Eva Cizkova, Dasa |
author_sort | Hudakova, Nikola |
collection | PubMed |
description | Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all. |
format | Online Article Text |
id | pubmed-8224379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82243792021-06-25 Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2 Hudakova, Nikola Hricikova, Simona Kulkarni, Amod Bhide, Mangesh Kontsekova, Eva Cizkova, Dasa Pathogens Review Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all. MDPI 2021-05-21 /pmc/articles/PMC8224379/ /pubmed/34064300 http://dx.doi.org/10.3390/pathogens10060636 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hudakova, Nikola Hricikova, Simona Kulkarni, Amod Bhide, Mangesh Kontsekova, Eva Cizkova, Dasa Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2 |
title | Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2 |
title_full | Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2 |
title_fullStr | Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2 |
title_full_unstemmed | Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2 |
title_short | Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2 |
title_sort | fundamental and advanced therapies, vaccine development against sars-cov-2 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224379/ https://www.ncbi.nlm.nih.gov/pubmed/34064300 http://dx.doi.org/10.3390/pathogens10060636 |
work_keys_str_mv | AT hudakovanikola fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2 AT hricikovasimona fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2 AT kulkarniamod fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2 AT bhidemangesh fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2 AT kontsekovaeva fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2 AT cizkovadasa fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2 |